NCT07699250Completed
Foxtail Millet Based Dietary Intervention for Postprandial Glycemic Management Among Obese Diabetic Patients
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
This randomized controlled trial evaluated the effectiveness of foxtail millet (Setaria italica (L.) P. Beauv.) muffin supplementation on postprandial glycemic management among obese patients with type 2 diabetes mellitus. A total of 102 participants aged 30-60 years were randomly assigned to three groups for 10 weeks: T₀ (50 g wheat muffin with usual diet), T₁ (50 g foxtail millet muffin once daily), and T₂ (50 g foxtail millet muffin twice daily combined with a low glycemic index diet). Anthropometric indices, glycemic markers, lipid profile, and liver function parameters were assessed before and after intervention. The results demonstrated significant improvements in metabolic outcomes, particularly in the T₂ group. Participants receiving foxtail millet muffins twice daily exhibited substantial reductions in body weight, BMI, fasting blood glucose, and HbA1c levels. Significant improvements were also observed in lipid parameters, including decreased total cholesterol, triglycerides, and LDL cholesterol, along with increased HDL cholesterol concentrations. Favorable changes in liver function markers further indicated enhanced metabolic health. Sensory evaluation confirmed good acceptability and palatability of the foxtail millet muffins. Overall, the findings suggest that regular consumption of foxtail millet muffins, especially when combined with a low glycemic index diet, is an effective dietary strategy for improving glycemic control, reducing obesity-related risk factors, and promoting metabolic health in obese diabetic patients.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 102 (actual)
- First submitted
- 28 Jun 2026
- Start date
- 10 Apr 2025
- Primary completion date
- 25 Jul 2025
- Lead sponsor
- University of Lahore
- Diseases
- Obesity
- NCT number
- NCT07699250
What you commit to
- Study type: Interventional
- Participants enrolled: 102
- From 10 Apr 2025 to the primary completion date, 25 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- People between 30 to 60 years old
- Body Mass Index (BMI) ≥30.0 kg/m²
- Fasting blood glucose levels ≥ 7.0 mmol/L (126 mg/dL)
- Individuals having HbA1c ≥ 6.5%
- Elevated Lipid Profile: TC \> 200 mg/dL, TG \> 150 mg/dL, LDL-C \> 100 mg/dL, HDL-C \< 40 mg/dL (men) / \< 50 mg/dL (women)
- Elevated Liver Function Tests: ALT \> 56 U/L, AST \> 40 U/L, ALP \> 147 U/L, Total Bilirubin \> 1.2 mg/dL, Albumin \< 3.5 g/dL ii. Exclusion Criteria
- Individuals who have a known allergy or have experienced any adverse reaction to foxtail millet or any of the ingredients used in the muffins will not be included in the study
- Patients who are taking medications known to significantly alter glucose metabolism or gastrointestinal absorption
- Individuals who have recently had gastric surgery or who have surgery planned during the research period
- Presence of other severe chronic diseases (e.g., severe renal, hepatic, or cardiovascular disease, active cancer)
- Nursing or pregnant females
Age in the registry: 30 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sana Noreen Coordinator of this site? Confirm its status | Lahore | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.